Middle East & Africa Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis ­– by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-base

Middle East & Africa Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis ­– by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), Route of Administration (Injection and Nasal Spray), and Target Group (Infants, Children, Adults, and Elderly People)

The Middle East & Africa influenza vaccines market is expected to grow from US$ 374.35 million in 2022 to US$ 533.85 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2022 to 2028.

Increase in Government Support to Promote Influenza Vaccination to Bolster Middle East & Africa Influenza Vaccines Market During Forecast Period

Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats in the Middle East & Africa. Thus, strong pipeline candidates for influenza vaccines are the latest trend in the Middle East & Africa influenza vaccines market.

Market Overview

The Middle East & Africa influenza vaccines market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. In 2022, South Africa was the largest market for influenza vaccines in the region. The market for influenza vaccines in the Middle East & Africa is anticipated to grow at a CAGR of 6.1% during the forecast period. The influenza vaccines market is expected to grow due to the rising population base, increasing cases of influenza, growing research studies across the region, and increasing healthcare facilities.

Middle East & Africa Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Influenza Vaccines Market Segmentation

The Middle East & Africa influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the Middle East & Africa influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the Middle East & Africa influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the Middle East & Africa influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the Middle East & Africa influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the Middle East & Africa influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the Middle East & Africa influenza vaccines market is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

AstraZeneca; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the Middle East & Africa influenza vaccines market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa influenza vaccines market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa influenza vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution